Results 1 to 10 of about 803,874 (212)

Apolipoprotein A-I modulates HDL particle size in the absence of apolipoprotein A-II [PDF]

Journal of Lipid Research, 2021
Human high-density lipoproteins (HDLs) are a complex mixture of structurally related nanoparticles that perform distinct physiological functions. We previously showed that human HDL containing apolipoprotein A-I (APOA1) but not apolipoprotein A-II (APOA2)
John T. Melchior, Scott E. Street, Tomas Vaisar, Rachel Hart, Jay Jerome, Zsuzsanna Kuklenyik, Noemie Clouet-Foraison, Carissa Thornock, Shimpi Bedi, Amy S. Shah, Jere P. Segrest, Jay W. Heinecke, W. Sean Davidson   +12 more
doaj   +6 more sources

Apolipoprotein A-II, a Player in Multiple Processes and Diseases [PDF]

Biomedicines, 2022
Apolipoprotein A-II (apoA-II) is the second most abundant apolipoprotein in high-density lipoprotein (HDL) particles, playing an important role in lipid metabolism.
Gabriela Florea, Irina Florina Tudorache, Elena Valeria Fuior, Radu Ionita, Madalina Dumitrescu, Ioana Madalina Fenyo, Violeta Georgeta Bivol, Anca Violeta Gafencu   +7 more
doaj   +5 more sources

C-terminal sequence of amyloid-resistant type F apolipoprotein A-II inhibits amyloid fibril formation of apolipoprotein A-II in mice. [PDF]

Proc Natl Acad Sci U S A, 2015
Significance Apolipoprotein (apo) A-II is the most important protein associated with senile amyloidosis. Because some variants of apoA-II protein have been found among inbred strains of mice, we hypothesized that investigating amyloidogenesis of the variants would improve our understanding of the molecular and biological mechanisms of senile ...
Sawashita J, Zhang B, Hasegawa K, Mori M, Naiki H, Kametani F, Higuchi K.   +6 more
europepmc   +5 more sources

Ceruloplasmin, transferrin and apolipoprotein A-II play important role in treatment's follow-up of paracoccidioidomycosis patients. [PDF]

PLoS One, 2018
Paracoccidioidomycosis (PCM) is a systemic disease caused by thermodymorphic fungi of the Paracoccidioides brasiliensis complex, (Paracoccidioides spp.). Patients with PCM reveal specific cellular immune impairment.
Sylvestre TF, Cavalcante RS, da Silva JF, Paniago AMM, Weber SS, Pauletti BA, de Carvalho LR, Dos Santos LD, Mendes RP.   +8 more
europepmc   +2 more sources

Hereditary Renal Amyloidosis Associated With a Novel Apolipoprotein A-II Variant. [PDF]

Kidney Int Rep, 2017
To the Editor: Systemic amyloidosis is characterized by the extracellular deposition of misfolded proteins as insoluble amyloid fibrils in various tissues.
Prokaeva T, Akar H, Spencer B, Havasi A, Cui H, O'Hara CJ, Gursky O, Leszyk J, Steffen M, Browning S, Rosenberg A, Connors LH.   +11 more
europepmc   +2 more sources

Apolipoprotein A-II alters the proteome of human lipoproteins and enhances cholesterol efflux from ABCA1. [PDF]

J Lipid Res, 2017
HDLs are a family of heterogeneous particles that vary in size, composition, and function. The structure of most HDLs is maintained by two scaffold proteins, apoA-I and apoA-II, but up to 95 other “accessory” proteins have been found associated with the ...
Melchior JT, Street SE, Andraski AB, Furtado JD, Sacks FM, Shute RL, Greve EI, Swertfeger DK, Li H, Shah AS, Lu LJ, Davidson WS.   +11 more
europepmc   +2 more sources

Human apolipoprotein A-II reduces atherosclerosis in knock-in rabbits. [PDF]

Atherosclerosis, 2021
Background and aims: Apolipoprotein A-II (apoAII) is the second major apolipoprotein of the high-density lipoprotein (HDL) particle, after apoAI. Unlike apoAI, the biological and physiological functions of apoAII are unclear. We aimed to gain insight into the specific roles of apoAII in lipoprotein metabolism and atherosclerosis using a novel rabbit ...
Koike T, Koike Y, Yang D, Guo Y, Rom O, Song J, Xu J, Chen Y, Wang Y, Zhu T, Garcia-Barrio MT, Fan J, Chen YE, Zhang J.   +13 more
europepmc   +5 more sources

Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism [PDF]

Journal of Lipid Research, 2009
This study was designed to establish the mechanism responsible for the increased apolipoprotein (apo) A-II levels caused by the cholesteryl ester transfer protein inhibitor torcetrapib. Nineteen subjects with low HDL cholesterol (
Margaret E. Brousseau, John S. Millar, Margaret R. Diffenderfer, Chorthip Nartsupha, Bela F. Asztalos, Megan L. Wolfe, James P. Mancuso, Andres G. Digenio, Daniel J. Rader, Ernst J. Schaefer   +9 more
doaj   +3 more sources

Protein heterogeneity of lipoprotein particles containing apolipoprotein A-I without apolipoprotein A-II and apolipoprotein A-I with apolipoprotein A-II isolated from human plasma.

Journal of Lipid Research, 1988
The protein heterogeneity of fractions isolated by immunoaffinity chromatography on anti-apolipoprotein A-I and anti-apolipoprotein A-II affinity columns was analyzed by high resolution two-dimensional gel electrophoresis.
R W James, D Hochstrasser, J D Tissot, M Funk, R Appel, F Barja, C Pellegrini, A F Muller, D Pometta   +8 more
doaj   +3 more sources

Low apolipoprotein A-II levels causally contribute to increased mortality in septic shock [PDF]

Journal of Intensive Care
Background Lipoproteins and their component apolipoproteins play an important role in sepsis. However, little is known with regard to the association and causal contribution of these proteins to mortality in patients of different ancestries following ...
Nozomi Takahashi, Kyle R. Campbell, Tadanaga Shimada, Taka-aki Nakada, James A. Russell, Keith R. Walley   +5 more
doaj   +2 more sources